[go: up one dir, main page]

AR057891A1 - Compuestos de oxazol y composicion farmaceutica - Google Patents

Compuestos de oxazol y composicion farmaceutica

Info

Publication number
AR057891A1
AR057891A1 ARP060104973A ARP060104973A AR057891A1 AR 057891 A1 AR057891 A1 AR 057891A1 AR P060104973 A ARP060104973 A AR P060104973A AR P060104973 A ARP060104973 A AR P060104973A AR 057891 A1 AR057891 A1 AR 057891A1
Authority
AR
Argentina
Prior art keywords
groups
group
lower alkoxy
independently
formula
Prior art date
Application number
ARP060104973A
Other languages
English (en)
Inventor
Norifumi Sato
Tetsuyuki Uno
Minoru Okada
Masaya Kato
Junpei Haruta
Hideki Kitagaki
Hidetaka Hiyama
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR057891A1 publication Critical patent/AR057891A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion provee un compuesto de oxazol representado por la Formula (1), o una sal del mismo y una composicion farmacéutica Reivindicacion 1: Un compuesto de oxazol representado por la Formula (1): caracterizado porque R1 es un grupo arilo que puede tener uno o más sustituyentes seleccionados entre los siguientes: grupos hidroxi, grupos alcoxi inferior sustituidos con halogeno o no sustituidos, grupos alqueniloxi inferior, grupos alquiniloxi inferior, grupos ciclo alquilo C3-8 alcoxi inferior, grupos ciclo alquiloxi C3-8, grupos ciclo alqueniloxi C3-8, grupos dihidroindeniloxi, grupos hidroxi alcoxi inferior, grupos oxiranil alcoxi inferior, y grupos hidroxi protegidos; R2 es un grupo arilo o un grupo heterocíclico que contiene un atomo de nitrogeno, cada uno de los cuales puede tener uno o más sustituyentes seleccionados entre los siguientes: grupos hidroxi, grupos alcoxi inferior sustituidos con halogeno o no sustituidos, grupos alquilo inferior sustituidos con halogeno o no sustituidos, grupos alqueniloxi inferior, átomos de halogeno, grupos alcanoilo inferior, grupos alquiltio inferior, grupos alquilsulfonilo inferior, grupos oxo, y grupos alcoxi inferior alcoxi inferior; y W es un grupo divalente representado por la Formula -Y1-A1 o -Y2-C(=O)-; en donde A1 es un grupo alquenileno inferior, o un grupo alquileno inferior que puede tener uno o más sustituyentes seleccionados entre el grupo que consiste en grupos hidroxi y grupos alcoxicarbonilo inferior, Y1 es un enlace directo, -C(=O)-, -C(=O)-N(R3)-, -N(R4)-C(=O)-, -S(O)m-NH-, o -S(O)n- en donde R3 y R4 son cada uno independientemente un átomo de hidrogeno o un grupo alquilo inferior, y m y n son cada uno independientemente un entero de 0 a 2, e Y2 es un grupo piperazinadiilo, o un grupo divalente representado por la Formula -C(=O)-A2-N(R5)- o -A3-N(R6)-; en donde A2 y A3 son cada uno independientemente un grupo alquileno inferior, y R5 y R6 son cada uno independientemente un átomo de hidrogeno o un grupo alquilo inferior; o una sal del mismo. El compuesto de oxazol tiene una accion inhibidora específica contra la fosfodiesterasa 4 y es util para enfermedades de la piel, en especial la dermatitis atopica.
ARP060104973A 2005-11-15 2006-11-14 Compuestos de oxazol y composicion farmaceutica AR057891A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005330590 2005-11-15

Publications (1)

Publication Number Publication Date
AR057891A1 true AR057891A1 (es) 2007-12-26

Family

ID=37879936

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP060104973A AR057891A1 (es) 2005-11-15 2006-11-14 Compuestos de oxazol y composicion farmaceutica
ARP170101905A AR109007A2 (es) 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica
ARP170101904A AR109006A2 (es) 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP170101905A AR109007A2 (es) 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica
ARP170101904A AR109006A2 (es) 2005-11-15 2017-07-10 Compuesto de oxazol y composición farmacéutica

Country Status (22)

Country Link
US (8) USRE46792E1 (es)
EP (1) EP1954684B1 (es)
JP (1) JP5305914B2 (es)
KR (1) KR101439557B1 (es)
CN (1) CN101309912B (es)
AR (3) AR057891A1 (es)
AU (1) AU2006316079B2 (es)
BR (1) BRPI0618589B8 (es)
CA (1) CA2627541C (es)
CY (1) CY1115302T1 (es)
DK (1) DK1954684T3 (es)
ES (1) ES2483992T3 (es)
IL (1) IL191008A (es)
MY (1) MY153720A (es)
NO (1) NO341440B1 (es)
PL (1) PL1954684T3 (es)
PT (1) PT1954684E (es)
RU (1) RU2418793C2 (es)
SI (1) SI1954684T1 (es)
TW (1) TWI330639B (es)
WO (1) WO2007058338A2 (es)
ZA (1) ZA200803758B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986927B2 (ja) * 2007-05-14 2012-07-25 大塚製薬株式会社 医薬
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
JP5507552B2 (ja) 2008-06-16 2014-05-28 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌を処置するための化合物
US8822513B2 (en) 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
GB2465890A (en) * 2008-12-05 2010-06-09 Scynexis Inc 2-Arylazole derivatives as antiprotozoal agents
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
CN103002742B (zh) 2010-03-05 2016-07-13 卡尔约药物治疗公司 核转运调节剂及其应用
KR101512548B1 (ko) * 2010-03-12 2015-04-15 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
CA2824808A1 (en) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
KR20200088518A (ko) 2011-07-29 2020-07-22 카리오팜 쎄라퓨틱스, 인코포레이티드 하이드라지드 함유 핵 수송 조절인자 및 이의 용도
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN104080770A (zh) 2011-11-09 2014-10-01 迈兰实验室有限公司 用于制备罗氟司特的改进方法
HUE040427T2 (hu) 2012-05-09 2019-03-28 Biogen Ma Inc Nukleáris transzportmodulátorok és felhasználásuk
WO2014034958A1 (en) 2012-08-30 2014-03-06 Otsuka Pharmaceutical Co., Ltd. Method for producing oxazole compound
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
MX365939B (es) 2013-06-21 2019-06-19 Karyopharm Therapeutics Inc Moduladores del transporte nuclear y usos de los mismos.
CN105085429B (zh) * 2014-04-25 2019-12-10 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
SG11201700789SA (en) 2014-08-15 2017-02-27 Karyopharm Therapeutics Inc Polymorphs of selinexor
TWI689497B (zh) * 2014-09-04 2020-04-01 南北兄弟藥業投資有限公司 芳雜環類衍生物及其在藥物中的應用
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
CN106188027B (zh) * 2015-09-02 2020-10-20 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
TWI726027B (zh) * 2015-12-28 2021-05-01 日商大塚製藥股份有限公司 軟膏
CN106279138B (zh) * 2015-12-29 2019-03-01 广东东阳光药业有限公司 芳杂环类衍生物及其在药物中的应用
US10709706B2 (en) 2015-12-31 2020-07-14 Karopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
SG11202009564TA (en) * 2018-04-04 2020-10-29 Otsuka Pharma Co Ltd Oxazole compound crystal
TW202227424A (zh) * 2020-11-27 2022-07-16 大陸商瑞石生物醫藥有限公司 芳基或雜芳基取代５員芳雜環化合物及其用途
CN112425610A (zh) * 2021-01-22 2021-03-02 深圳市洛奇机电科技有限公司 一种防治君子兰叶斑病的农药悬浮剂的制备系统及其应用
JPWO2023182468A1 (es) 2022-03-25 2023-09-28
CN115785014B (zh) * 2022-12-27 2025-01-24 瑞石生物医药有限公司 四唑衍生物及其用途
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy
WO2025249530A1 (en) 2024-05-29 2025-12-04 Otsuka Pharmaceutical Co., Ltd. Difamilast-containing composition

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735961A (en) * 1984-05-07 1988-04-05 Merck & Co., Inc. Oxazoles and thiazoles containing an aminohydroxypropoxyphenyl moiety
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
US20020169173A1 (en) 1993-11-08 2002-11-14 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
WO1996000218A1 (en) 1994-06-24 1996-01-04 Euro-Celtique, S.A. Compounds for and method of inhibiting phosphodiesterase iv
AUPO156596A0 (en) 1996-08-09 1996-09-05 University Of Sydney, The Synthetic polynucleotides
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
AU4015497A (en) * 1996-08-26 1998-03-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Thiazole derivatives useful as selective inhibitors of pde-iv
NZ335610A (en) 1996-10-07 2000-10-27 Lilly Co Eli Phenyl oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazole compounds useful as neuro-protective agents
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
JP4518587B2 (ja) 1998-03-09 2010-08-04 興和創薬株式会社 ２−フェニルモルホリン誘導体
AR036237A1 (es) * 2001-07-27 2004-08-25 Bayer Corp Derivados del acido indan acetico, intermediarios, y metodo para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento
EP1435944B1 (en) 2001-10-16 2009-09-30 Memory Pharmaceutical Corporation 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
WO2003072102A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
JP2004203871A (ja) * 2002-12-13 2004-07-22 Yamanouchi Pharmaceut Co Ltd 医薬組成物
TW200505913A (en) 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
WO2005111007A1 (ja) 2004-05-17 2005-11-24 Otsuka Pharmaceutical Co., Ltd. チアゾール化合物及びその用途
DK1786790T3 (da) 2004-07-26 2009-07-20 Lilly Co Eli Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser
DE102004051277A1 (de) * 2004-10-21 2006-04-27 Merck Patent Gmbh Heterocyclische Carbonylverbindungen
EP1866293A1 (en) * 2005-03-31 2007-12-19 UCB Pharma, S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses

Also Published As

Publication number Publication date
US20090221586A1 (en) 2009-09-03
TWI330639B (en) 2010-09-21
AR109007A2 (es) 2018-10-17
US20220265613A1 (en) 2022-08-25
NO341440B1 (no) 2017-11-13
NO20081930L (no) 2008-06-10
CA2627541C (en) 2014-12-30
US20190070151A1 (en) 2019-03-07
AR109006A2 (es) 2018-10-17
ZA200803758B (en) 2009-08-26
IL191008A (en) 2013-10-31
SI1954684T1 (sl) 2014-07-31
US8637559B2 (en) 2014-01-28
WO2007058338A9 (en) 2007-08-30
US20200078340A1 (en) 2020-03-12
KR101439557B1 (ko) 2014-09-11
WO2007058338A2 (en) 2007-05-24
ES2483992T3 (es) 2014-08-08
CN101309912A (zh) 2008-11-19
MY153720A (en) 2015-03-13
JP5305914B2 (ja) 2013-10-02
AU2006316079B2 (en) 2012-03-29
DK1954684T3 (da) 2014-06-30
PL1954684T3 (pl) 2014-10-31
EP1954684A2 (en) 2008-08-13
BRPI0618589B8 (pt) 2021-05-25
USRE46792E1 (en) 2018-04-17
EP1954684B1 (en) 2014-05-07
TW200732332A (en) 2007-09-01
CA2627541A1 (en) 2007-05-24
BRPI0618589A2 (pt) 2012-07-03
BRPI0618589B1 (pt) 2020-11-17
US20240148699A1 (en) 2024-05-09
PT1954684E (pt) 2014-07-17
HK1121162A1 (en) 2009-04-17
US20170216260A1 (en) 2017-08-03
US20140100226A1 (en) 2014-04-10
WO2007058338A3 (en) 2007-07-19
CY1115302T1 (el) 2017-01-04
RU2418793C2 (ru) 2011-05-20
RU2008123839A (ru) 2009-12-27
AU2006316079A1 (en) 2007-05-24
JP2009515872A (ja) 2009-04-16
CN101309912B (zh) 2013-09-25
KR20080073337A (ko) 2008-08-08

Similar Documents

Publication Publication Date Title
AR057891A1 (es) Compuestos de oxazol y composicion farmaceutica
AR049647A1 (es) Cis-imidazolinas
ECSP099461A (es) Compuesto heteromonocíclico y uso del mismo
AR059622A1 (es) Quinolonas utiles como inhibidores de la sintetasa del oxido nitrico inducibles
CO6321166A2 (es) Compuestos de pirrol
PE20090042A1 (es) Analogos de ciclopamina
AR050932A1 (es) Amidas biciclicas como inhibidores de cinasa
ECSP088724A (es) Nuevo derivado de coumarina que tiene actividad antitumor
ES2640911T3 (es) Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus
AR074459A1 (es) Pirrolopirazinil-ureas utiles para el tratamiento de enfermedades autoinmunes e inflamatorias.
ES2352576T3 (es) Inhibidiores de la replicación del virus de la inmunodeficiencia humana.
AR073412A1 (es) Derivados de espiro imidazolona como antagonistas del receptor glucagon y composiciones que los comprende.
AR077935A1 (es) Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
EA200700141A1 (ru) Новые аминоциклические производные мочевины, их получение и фармацевтическое применение в качестве ингибиторов киназы
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
AR066972A1 (es) Derivados azapeptidicos
WO2008126693A1 (ja) ミトコンドリア障害脳疾患治療剤及び診断剤
CO6460726A2 (es) Derivado de 5-hidroxi-pirimidin-4-carboxamida
AR055613A1 (es) Formas cristalinas delta y epsilon de mesilato de imatinib
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
AR071531A1 (es) Compuesto cristalino heteromonociclico
AR077367A1 (es) 2- carboxamida -cicloamino-ureas sustituidas
AR082111A1 (es) Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas
AR078098A1 (es) Compuesto que contiene nitrogeno y composicion farmaceutica

Legal Events

Date Code Title Description
FG Grant, registration